NCT06932107

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 518 (actual)
• Sponsor: Qilu Pharmaceutical (Hainan) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The goal of this Interventional study is to evaluate the efficacy and safety of Aprepitant Injection(QLG2174) for preventing PONV in Chinese patients.

Conditions

• Postoperative Nausea and Vomiting

Interventions

Type	Name	Description
DRUG	Aprepitant Injection	Before anesthesia induction, 4.4ml(32mg） was given by a single intravenous injection, which was completed within 30 seconds
DRUG	Aprepitant Injection Placebo	Before anesthesia induction, 4.4ml was given by a single intravenous injection, which was completed within 30 seconds

Timeline

• Start date: 2024-02-02
• Primary completion: 2024-05-28
• Completion: 2024-06-05
• First posted: 2025-04-17
• Last updated: 2025-04-23

Locations

1 site across 1 country: China